Draft monograph: Petrelintide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Trials are described as terminated where they completed as planned — arising from DRAFT-PETRELINTIDE/009. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
2. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-PETRELINTIDE/012. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
3. The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-PETRELINTIDE/002. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
4. The certainty rating for the principal assessed outcome cannot be traced to the contributing trials — arising from DRAFT-PETRELINTIDE/011. Each assessed outcome now carries its downgrade domains in the summary-of-findings row, with a short statement of the judgement made in each, so that the rating can be checked domain by domain against the contributing trials.
5. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-PETRELINTIDE/001. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
6. The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-PETRELINTIDE/004. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
7. A purity figure from a certificate is quoted as though it were a content figure — arising from DRAFT-PETRELINTIDE/015. Purity and content are now reported in separate rows with separate definitions, and the monograph states that a purity figure sets no bound on content and that a content figure requires a determination against a standard of assigned content.
8. Regulatory status is stated without naming the jurisdiction — arising from DRAFT-PETRELINTIDE/010. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
9. Point estimates are given without an interval — arising from DRAFT-PETRELINTIDE/006. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
10. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-PETRELINTIDE/003. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
11. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-PETRELINTIDE/008. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
12. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-PETRELINTIDE/013. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
13. Quantitative claims are reproduced without the method that produced them — arising from DRAFT-PETRELINTIDE/014. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
14. The preclinical section is extensive and the clinical section is not — arising from DRAFT-PETRELINTIDE/007. The preclinical section is reduced in length, placed after the clinical assessment rather than before it, and opens with a standing statement that an effect observed in an animal model is not a clinical outcome and does not support a certainty rating.
15. The document is unreadable without specialist training — arising from DRAFT-PETRELINTIDE/005. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.